<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Laser photocoagulation for proliferative diabetic retinopathy - Evans, JR - 2014 | Cochrane Library</title> <meta content="Laser photocoagulation for proliferative diabetic retinopathy - Evans, JR - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011234.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Laser photocoagulation for proliferative diabetic retinopathy - Evans, JR - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011234.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011234.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Laser photocoagulation for proliferative diabetic retinopathy" name="citation_title"/> <meta content="Jennifer R Evans" name="citation_author"/> <meta content="London School of Hygiene &amp; Tropical Medicine" name="citation_author_institution"/> <meta content="jennifer.evans@lshtm.ac.uk" name="citation_author_email"/> <meta content="Manuele Michelessi" name="citation_author"/> <meta content="Fondazione G.B. Bietti per lo studio e la ricerca in Oftalmolologia‐IRCCS" name="citation_author_institution"/> <meta content="Gianni Virgili" name="citation_author"/> <meta content="University of Florence" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD011234.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/11/24" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011234.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011234.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011234.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Diabetic Retinopathy [*surgery]; Disease Progression; Laser Coagulation [*methods]; Randomized Controlled Trials as Topic; Time Factors; Vision Disorders [etiology]; Visual Acuity; Vitreoretinopathy, Proliferative [*surgery]; Watchful Waiting" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011234.pub2&amp;doi=10.1002/14651858.CD011234.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="XHP2gG4h";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011234\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011234\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011234\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011234\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011234.pub2",title:"Laser photocoagulation for proliferative diabetic retinopathy",firstPublishedDate:"Nov 24, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XHP2gG4h&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011234.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011234.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011234.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011234.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011234.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011234.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011234.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011234.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011234.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011234.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4925 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011234.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/full#CD011234-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/full#CD011234-sec-0076"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/full#CD011234-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/full#CD011234-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/full#CD011234-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/full#CD011234-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/full#CD011234-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/full#CD011234-sec-0070"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/appendices#CD011234-sec-0081"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/table_n/CD011234StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/table_n/CD011234StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Laser photocoagulation for proliferative diabetic retinopathy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/information#CD011234-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Jennifer R Evans</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/information#CD011234-cr-0003">Manuele Michelessi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011234.pub2/information#CD011234-cr-0004">Gianni Virgili</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/information/en#CD011234-sec-0091">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 24 November 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011234.pub2">https://doi.org/10.1002/14651858.CD011234.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011234-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011234-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011234-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011234-abs-0008">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011234-abs-0001" lang="en"> <section id="CD011234-sec-0001"> <h3 class="title" id="CD011234-sec-0001">Background</h3> <p>Diabetic retinopathy is a complication of diabetes in which high blood sugar levels damage the blood vessels in the retina. Sometimes new blood vessels grow in the retina, and these can have harmful effects; this is known as proliferative diabetic retinopathy. Laser photocoagulation is an intervention that is commonly used to treat diabetic retinopathy, in which light energy is applied to the retina with the aim of stopping the growth and development of new blood vessels, and thereby preserving vision. </p> </section> <section id="CD011234-sec-0002"> <h3 class="title" id="CD011234-sec-0002">Objectives</h3> <p>To assess the effects of laser photocoagulation for diabetic retinopathy compared to no treatment or deferred treatment. </p> </section> <section id="CD011234-sec-0003"> <h3 class="title" id="CD011234-sec-0003">Search methods</h3> <p>We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2014, Issue 5), Ovid MEDLINE, Ovid MEDLINE In‐Process and Other Non‐Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to June 2014), EMBASE (January 1980 to June 2014), the <i>meta</i> Register of Controlled Trials (<i>m</i>RCT) (<a href="http://www.controlled-trials.com/" target="_blank">www.controlled‐trials.com</a>), ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/search/en" target="_blank">www.who.int/ictrp/search/en</a>). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 3 June 2014. </p> </section> <section id="CD011234-sec-0004"> <h3 class="title" id="CD011234-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) where people (or eyes) with diabetic retinopathy were randomly allocated to laser photocoagulation or no treatment or deferred treatment. We excluded trials of lasers that are no longer in routine use. Our primary outcome was the proportion of people who lost 15 or more letters (3 lines) of best‐corrected visual acuity (BCVA) as measured on a logMAR chart at 12 months. We also looked at longer‐term follow‐up of the primary outcome at two to five years. Secondary outcomes included mean best corrected distance visual acuity, severe visual loss, mean near visual acuity, progression of diabetic retinopathy, quality of life, pain, loss of driving licence, vitreous haemorrhage and retinal detachment. </p> </section> <section id="CD011234-sec-0005"> <h3 class="title" id="CD011234-sec-0005">Data collection and analysis</h3> <p>We used standard methods as expected by the Cochrane Collaboration. Two review authors selected studies and extracted data. </p> </section> <section id="CD011234-sec-0006"> <h3 class="title" id="CD011234-sec-0006">Main results</h3> <p>We identified a large number of trials of laser photocoagulation of diabetic retinopathy (n = 83) but only five of these studies were eligible for inclusion in the review, i.e. they compared laser photocoagulation with currently available lasers to no (or deferred) treatment. Three studies were conducted in the USA, one study in the UK and one study in Japan. A total of 4786 people (9503 eyes) were included in these studies. The majority of participants in four of these trials were people with proliferative diabetic retinopathy; one trial recruited mainly people with non‐proliferative retinopathy. Four of the studies evaluated panretinal photocoagulation with argon laser and one study investigated selective photocoagulation of non‐perfusion areas. Three studies compared laser treatment to no treatment and two studies compared laser treatment to deferred laser treatment. All studies were at risk of performance bias because the treatment and control were different and no study attempted to produce a sham treatment. Three studies were considered to be at risk of attrition bias. </p> <p>At 12 months there was little difference between eyes that received laser photocoagulation and those allocated to no treatment (or deferred treatment), in terms of loss of 15 or more letters of visual acuity (risk ratio (RR) 0.99, 95% confidence interval (CI) 0.89 to 1.11; 8926 eyes; 2 RCTs, low quality evidence). Longer term follow‐up did not show a consistent pattern, but one study found a 20% reduction in risk of loss of 15 or more letters of visual acuity at five years with laser treatment. Treatment with laser reduced the risk of severe visual loss by over 50% at 12 months (RR 0.46, 95% CI 0.24 to 0.86; 9276 eyes; 4 RCTs, moderate quality evidence). There was a beneficial effect on progression of diabetic retinopathy with treated eyes experiencing a 50% reduction in risk of progression of diabetic retinopathy (RR 0.49, 95% CI 0.37 to 0.64; 8331 eyes; 4 RCTs, low quality evidence) and a similar reduction in risk of vitreous haemorrhage (RR 0.56, 95% CI 0.37 to 0.85; 224 eyes; 2 RCTs, low quality evidence). </p> <p>None of the studies reported near visual acuity or patient‐relevant outcomes such as quality of life, pain, loss of driving licence or adverse effects such as retinal detachment. </p> <p>We did not plan any subgroup analyses, but there was a difference in baseline risk in participants with non‐proliferative retinopathy compared to those with proliferative retinopathy. With the small number of included studies we could not do a formal subgroup analysis comparing effect in proliferative and non‐proliferative retinopathy. </p> </section> <section id="CD011234-sec-0007"> <h3 class="title" id="CD011234-sec-0007">Authors' conclusions</h3> <p>This review provides evidence that laser photocoagulation is beneficial in treating proliferative diabetic retinopathy. We judged the evidence to be moderate or low, depending on the outcome. This is partly related to reporting of trials conducted many years ago, after which panretinal photocoagulation has become the mainstay of treatment of proliferative diabetic retinopathy. </p> <p>Future Cochrane Reviews on variations in the laser treatment protocol are planned. Future research on laser photocoagulation should investigate the combination of laser photocoagulation with newer treatments such as anti‐vascular endothelial growth factors (anti‐VEGFs). </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011234-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011234-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011234-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011234-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011234-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011234-abs-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011234-abs-0003">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011234-abs-0002" lang="en"> <h3>Laser photocoagulation for proliferative diabetic retinopathy</h3> <p><b>Review question</b> </p> <p>Is laser photocoagulation an effective treatment for diabetic retinopathy?</p> <p><b>Background</b> </p> <p>Diabetic retinopathy (DR) is a common problem for people with diabetes and can lead to loss of vision. The back of the eye (retina) can develop problems because of diabetes, including the growth of harmful new blood vessels (proliferative DR, referred to here as 'PDR'). Laser photocoagulation is a commonly used treatment for DR in which the eye doctor uses a laser on the back of the eye to stop some of the harmful changes. </p> <p><b>Study characteristics</b> </p> <p>We found five studies. The searches were done in April 2014. Three studies were done in the USA, one study in the UK and one study in Japan. A total of 4786 people (9503 eyes) were included in these studies. Most participants had PDR. </p> <p><b>Key results</b> </p> <p>We found that moderate vision loss at 12 months was similar in eyes treated with laser and eyes that were not treated, but similar assessments made at a later date showed that eyes treated with laser were less likely to have suffered moderate vision loss. Treatment with laser reduced the risk of severe visual loss by over 50% at 12 months. There was a similar effect on the progression of DR. None of the studies reported patient‐relevant outcomes such as pain or loss of driving licence. </p> <p><b>Quality of the evidence</b> </p> <p>We did not find very many studies and those we found were done quite a long time ago when standards of trial conduct and reporting were lower. We judged the quality of the evidence to be low, with the exception of the results for severe visual loss, which we judged to be moderate quality evidence. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011234-sec-0076" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011234-sec-0076"></div> <h3 class="title" id="CD011234-sec-0077">Implications for practice</h3> <section id="CD011234-sec-0077"> <p>This review provides evidence that laser photocoagulation is beneficial in treating diabetic retinopathy. There was not enough evidence to judge whether the effect of treatment is different in non‐proliferative and PDR, but based on the baseline risk of progression of the disease, and risk of visual loss, the current approach of caution in treating non‐proliferative DR with laser would appear to be justified. </p> <p>By current standards the quality of the evidence is not high, however, the effects on risk of progression and risk of severe visual loss are reasonably large (50% relative risk reduction). </p> </section> <h3 class="title" id="CD011234-sec-0078">Implications for research</h3> <section id="CD011234-sec-0078"> <p>Future Cochrane Reviews will examine specific questions regarding the treatment protocol for laser photocoagulation. </p> <p>Future trials on laser photocoagulation should focus on the combination with, and comparison to, newer interventions, such as anti‐vascular endothelial growth factor (anti‐VEGF) treatment. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011234-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011234-sec-0015"></div> <div class="table" id="CD011234-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Laser photocoagulation compared to control for diabetic retinopathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Laser photocoagulation compared to no treatment (or deferred treatment) for diabetic retinopathy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with diabetic retinopathy<br/> <b>Settings:</b> Ophthalmology clinics<br/> <b>Intervention:</b> laser photocoagulation<br/> <b>Comparison:</b> no treatment or deferred treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk*</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No treatment or deferred treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Laser photocoagulation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Loss of 15 or more letters BCVA</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low risk (non‐proliferative DR)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.99<br/> (0.89 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>8926<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The pooled RR 0.99 (0.89 to 1.11) is derived from one study with mainly low risk population RR 1.07 (0.92 to 1.23) and one study with mainly high risk population 0.86 (0.71 to 1.04) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>99 per 1000<br/> (89 to 111) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk (proliferative DR)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>248 per 1000<br/> (223 to 278) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCVA measured using logMAR acuity (0 = 6/6 visual acuity, higher score is worse visual acuity) </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BCVA at 12 months in the control group was 0.12 logMAR</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BCVA at 12 months in the intervention group was 0.02 logMAR units higher (worse; 0.23 lower to 0.27 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Severe visual loss (BCVA &lt; 6/60)</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low risk (non‐proliferative DR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>RR 0.46<br/> (0.24 to 0.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>9276<br/> (4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 per 1000<br/> (2 to 9) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High risk (proliferative DR)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>23 per 1000<br/> (12 to 43) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Progression of diabetic retinopathy</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low risk (non‐proliferative DR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>RR 0.49<br/> (0.37 to 0.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>8331<br/> (4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>⊕⊕⊝⊝<br/> LOW <sup>1,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>100 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>49 per 1000<br/> (37 to 64) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk (proliferative DR)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>400 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>196 per 1000</p> <p>(148 to 256)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> <p>Follow‐up: at time of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loss of driving licence</p> <p>Follow‐up: within three months of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>DR</b> : diabetic retinopathy; <b>BCVA</b>: Best corrected visual acuity </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Estimates of assumed risk are indicative only, as estimates at 12 months were not available in all studies. For the low risk populations they were estimated from ETDRS (but acknowledging that the control group received deferred laser) and for the high risk populations they were estimated from DRS and Hercules 1977. </p> <p><sup>1</sup>Downgraded for risk of bias (‐1): studies were not masked and treatment groups different </p> <p><sup>2</sup>Downgraded for inconsistency (‐1): I<sup>2</sup> = 69% and effect estimates were in different directions. See comments for details </p> <p><sup>3</sup>Downgraded for imprecision (‐1): wide confidence intervals </p> <p><sup>4</sup> There was heterogeneity (I<sup>2</sup> = 70%) but all effect estimates favoured laser photocoagulation so we did not downgrade for inconsistency </p> <p><sup>5</sup>Downgraded for indirectness (‐1): study results were reported at 1, 3, 4 and 5 years </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011234-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011234-sec-0016"></div> <section id="CD011234-sec-0017"> <h3 class="title" id="CD011234-sec-0017">Description of the condition</h3> <p>Diabetic retinopathy (DR) is a microvascular complication of diabetes in which high blood sugar levels damage the blood vessels in the retina (<a href="./references#CD011234-bbs2-0096" title="DavidsonJA , CiullaTA , McGillJB , KlesKA , AndersonPW . How the diabetic eye loses vision. Endocrine2007;32(1):107‐16. ">Davidson 2007</a>). These blood vessels may become blocked, which leads to a reduction or cessation of blood supply to the retina (non‐proliferative diabetic retinopathy). Sometimes the vessels swell up and leak fluid (macular oedema) and sometimes new vessels grow (neovascularisation) on the retina and vitreous (also called the vitreous humour); this is known as proliferative diabetic retinopathy (PDR). </p> <p>In general, the early stages of the disease are not associated with any symptoms. Disease progression is associated with visual loss and blindness, if left untreated. DR is an important cause of visual impairment worldwide. An estimated 285 million people are visually impaired and of these approximately 39 million people are blind (<a href="./references#CD011234-bbs2-0106" title="PascoliniD , MariottiSP . Global estimates of visual impairment: 2010. British Journal of Ophthalmology2012;96(5):614‐8. ">Pascolini 2012</a>). DR is believed to account for approximately 1% of visual impairment and blindness, meaning nearly three million people worldwide are visually impaired due to this condition. The total number of people with diabetes is projected to increase from 171 million people in 2000 to 366 million in 2030 (<a href="./references#CD011234-bbs2-0111" title="WildS , RoglicG , GreenA , SicreeR , KingH . Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care2004;27(5):1047‐53. ">Wild 2004</a>). </p> <p>This Cochrane Review is concerned with the treatment of DR, both proliferative and non‐proliferative, but not macular oedema which is addressed in another review (<a href="./references#CD011234-bbs2-0103" title="JorgeEC , JorgeEN , ElDibR . Laser photocoagulation for diabetic macular oedema. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD010859] ">Jorge 2013</a>). </p> </section> <section id="CD011234-sec-0018"> <h3 class="title" id="CD011234-sec-0018">Description of the intervention</h3> <p>Laser photocoagulation involves applying light energy to the retina. This is absorbed by the retinal pigments, which heat up and cause thermal damage to the retinal tissues. There are several types of laser: gas (argon, krypton), diode, dye and YAG (<a href="./references#CD011234-bbs2-0107" title="Royal College of Ophthalmologists. Diabetic Retinopathy Guidelines 2012. www.rcophth.ac.uk/page.asp?section=451 (accessed 14 March 2014). ">RCOphth 2012</a>). </p> <p> <div class="table" id="CD011234-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of laser</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Wavelength in nm (colour)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Argon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>488 (blue) 514 (green)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Krypton</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>568 (yellow) 647 (red)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dye laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>570 to 630, 577 (yellow) often used</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diode laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>810 (infrared)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Micropulse mode available</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Frequency‐doubled yttrium aluminium garnet (YAG) laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>532 (green) often used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pattern scan laser (PASCAL) often used</p> </td> </tr> </tbody> </table> </div> </p> <p>Laser application may focus on microaneurysms or be delivered in a grid‐pattern around the centre of the macula in people with diabetic macular oedema (DMO). When delivered to the peripheral retina, it may be focal, directed to neovascular tufts, or more commonly scattered, which is also known as panretinal photocoagulation (PRP) and in which 1200 to 2000 burns are applied to the peripheral retina. Laser photocoagulation may be applied in one session or may be delivered over several sessions to reduce the risk of adverse effects. </p> <p>Peripheral or panretinal laser treatment is commonly delivered to ischaemic areas (i.e. those with low oxygen levels) in the retinal periphery, with the aims of causing regression of retinal neovascularisation and prevention of visual loss due to vitreous haemorrhage, tractional retinal detachment, or neovascular glaucoma, which are the main causes of visual loss in patients with end‐stage PDR. Panretinal peripheral laser treatment was also initially proposed as a treatment that might prevent the occurrence of PDR. </p> </section> <section id="CD011234-sec-0019"> <h3 class="title" id="CD011234-sec-0019">How the intervention might work</h3> <p>The aim of laser photocoagulation is to slow down the growth of new blood vessels in the retina and thereby prevent the progression of visual loss (<a href="./references#CD011234-bbs2-0105" title="OckrimZ , YorstonD . Managing diabetic retinopathy. BMJ2010;341:c5400. ">Ockrim 2010</a>). Focal laser photocoagulation uses the heat of light to seal or destroy abnormal blood vessels in the retina. Individual vessels are treated with a small number of laser burns. </p> <p>PRP aims to slow down the growth of new blood vessels in a wider area of the retina. Many hundreds of laser burns are placed on the peripheral parts of the retina to stop blood vessels from growing (<a href="./references#CD011234-bbs2-0107" title="Royal College of Ophthalmologists. Diabetic Retinopathy Guidelines 2012. www.rcophth.ac.uk/page.asp?section=451 (accessed 14 March 2014). ">RCOphth 2012</a>). It is thought that the anatomic and functional changes that result from photocoagulation may improve the oxygen supply to the retina, and so reduce the stimulus for neovascularisation (<a href="./references#CD011234-bbs2-0109" title="StefanssonE . The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmologica Scandinavica2001;79(5):435‐40. ">Stefansson 2001</a>). Again the exact mechanisms are unclear, but it is possible that the decreased area of retinal tissue leads to improved oxygenation and a reduction in the levels of anti‐vascular endothelial growth factor. A reduction in levels of anti‐vascular endothelial growth factor may be important in reducing the risk of harmful new vessels forming. </p> </section> <section id="CD011234-sec-0020"> <h3 class="title" id="CD011234-sec-0020">Why it is important to do this review</h3> <p>Laser photocoagulation is a well‐established common treatment for DR and there are many different potential strategies for delivery of laser treatment that are likely to have different effects. A systematic review of the evidence for laser photocoagulation will provide important information on benefits and harms to guide treatment choices. With the advent of new treatments, especially the anti‐vascular endothelial growth factor (anti‐VEGF) agents, laser photocoagulation may become less commonly used in higher income countries, but may still have relevance as a potentially cost‐effective treatment in other parts of the world. This review should be read in conjunction with related Cochrane Reviews of treatment of DR, including laser photocoagulation for diabetic macular oedema (<a href="./references#CD011234-bbs2-0103" title="JorgeEC , JorgeEN , ElDibR . Laser photocoagulation for diabetic macular oedema. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD010859] ">Jorge 2013</a>), anti‐VEGF for proliferative retinopathy (<a href="./references#CD011234-bbs2-0104" title="Martinez‐ZapataMJ , Martí‐CarvajalAJ , SolàI , PijoánJI , Buil‐CalvoJA , CorderoJA , EvansJR . Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD008721.pub2] ">Martinez‐Zapata 2014</a>), anti‐VEGF for diabetic macular oedema (<a href="./references#CD011234-bbs2-0110" title="VirgiliG , ParravanoM , MenchiniF , BrunettiM . Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD007419.pub3] ">Virgili 2012</a>), and steroids for diabetic macular oedema (<a href="./references#CD011234-bbs2-0099" title="GroverD , LiT , ChongCC . Intravitreal steroids for macular edema in diabetes. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD005656.pub2] ">Grover 2008</a>). </p> <p>This is the first in a series of planned reviews on laser photocoagulation. Future reviews will compare different photocoagulation techniques. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011234-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011234-sec-0021"></div> <p>To assess the effects of laser photocoagulation for diabetic retinopathy compared to no treatment or deferred treatment. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011234-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011234-sec-0022"></div> <section id="CD011234-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011234-sec-0024"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) irrespective of the language in which they were published, or publication status (published or unpublished). </p> </section> <section id="CD011234-sec-0025"> <h4 class="title">Types of participants</h4> <p>People with pre‐proliferative (DR) or proliferative diabetic retinopathy (PDR). We excluded trials where the primary aim was to treat diabetic macular oedema as this is covered in a separate Cochrane Review (<a href="./references#CD011234-bbs2-0103" title="JorgeEC , JorgeEN , ElDibR . Laser photocoagulation for diabetic macular oedema. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD010859] ">Jorge 2013</a>). </p> </section> <section id="CD011234-sec-0026"> <h4 class="title">Types of interventions</h4> <p>We considered trials of peripheral laser photocoagulation with any ophthalmic laser at any wavelength, either focal or panretinal. We compared this to no treatment, sham treatment or deferred treatment. </p> <p>We included studies using any type of laser, but not studies using xenon arc photocoagulation or ruby laser, since these lasers have not been used for decades because of an observed increase in the risk of side‐effects, such as peripheral field damage and macular traction (<a href="./references#CD011234-bbs2-0097" title="Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: relationship of adverse treatment effects to retinopathy severity. Diabetic retinopathy study report no. 5. Developments in Ophthalmology1981;2:248‐61. ">DRS 1981</a>). </p> <p>We excluded trials that compared different types (wavelength) of laser, laser application at different powers or for different exposure times, and trials that compared different regimens for the application of the laser (e.g. compared the number, pattern or location of burns, or compared different numbers of treatment sessions) as these will be considered in future Cochrane Reviews. </p> <p>This review should be read in conjunction with related Cochrane Reviews that address the comparison between laser photocoagulation and other treatments such as anti‐VEGF (<a href="./references#CD011234-bbs2-0104" title="Martinez‐ZapataMJ , Martí‐CarvajalAJ , SolàI , PijoánJI , Buil‐CalvoJA , CorderoJA , EvansJR . Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD008721.pub2] ">Martinez‐Zapata 2014</a>; <a href="./references#CD011234-bbs2-0110" title="VirgiliG , ParravanoM , MenchiniF , BrunettiM . Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD007419.pub3] ">Virgili 2012</a>), and steroids (<a href="./references#CD011234-bbs2-0099" title="GroverD , LiT , ChongCC . Intravitreal steroids for macular edema in diabetes. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD005656.pub2] ">Grover 2008</a>). </p> </section> <section id="CD011234-sec-0027"> <h4 class="title">Types of outcome measures</h4> <section id="CD011234-sec-0028"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011234-list-0001"> <li> <p>Proportion of people who lose 15 or more letters (3 lines) of best‐corrected visual acuity (BCVA) as measured on a logMAR chart. </p> </li> </ul> </p> </section> <section id="CD011234-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011234-list-0002"> <li> <p>Mean distance visual acuity (BCVA).</p> </li> <li> <p>Mean near visual acuity (NVA).</p> </li> <li> <p>Severe visual loss (BCVA &lt; 6/60).</p> </li> <li> <p>Progression of diabetic retinopathy, as defined by trial investigators.</p> </li> <li> <p>Quality of life measured using any validated questionnaire.</p> </li> <li> <p>Adverse events: pain, loss of driving licence, vitreous haemorrhage, retinal detachment.</p> </li> </ol> </p> <p>With the exception of adverse events, we aimed to collect data on these outcomes at one year after initiation of treatment, which we defined as the period between six and 18 months. We considered adverse events at any time point, but these are most likely to occur within three months of treatment. We also planned to report the primary outcome at longer time periods ‐ two to five years ‐ in order to comment on whether any effects observed are sustained in the long term. </p> <p>We made some amendments to the outcomes from the protocol. See <a href="#CD011234-sec-0095">Differences between protocol and review</a>. </p> </section> </section> </section> <section id="CD011234-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011234-sec-0031"> <h4 class="title">Electronic searches</h4> <p>We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2014, Issue 5), Ovid MEDLINE, Ovid MEDLINE In‐Process and Other Non‐Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to June 2014), EMBASE (January 1980 to June 2014), the <i>meta</i> Register of Controlled Trials (<i>m</i>RCT) (<a href="http://www.controlled-trials.com/" target="_blank">www.controlled‐trials.com</a>), ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/search/en" target="_blank">www.who.int/ictrp/search/en</a>). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 3 June 2014. </p> <p>See: Appendices for details of search strategies for CENTRAL (<a href="./appendices#CD011234-sec-0082">Appendix 1</a>), MEDLINE (<a href="./appendices#CD011234-sec-0083">Appendix 2</a>), EMBASE (<a href="./appendices#CD011234-sec-0084">Appendix 3</a>), <i>m</i>RCT (<a href="./appendices#CD011234-sec-0085">Appendix 4</a>), ClinicalTrials.gov (<a href="./appendices#CD011234-sec-0086">Appendix 5</a>) and the ICTRP (<a href="./appendices#CD011234-sec-0087">Appendix 6</a>). </p> </section> <section id="CD011234-sec-0032"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of included studies and other reviews identified by the searches. </p> </section> </section> <section id="CD011234-sec-0033"> <h3 class="title" id="CD011234-sec-0033">Data collection and analysis</h3> <section id="CD011234-sec-0034"> <h4 class="title">Selection of studies</h4> <p>Two review authors (JE, MM) independently screened the search results and selected trials for inclusion. We resolved disagreements through discussion. </p> <p>We screened the list of citations and abstracts and classified records into 'possibly relevant' and 'definitely not relevant'. For the records we identified as 'possibly relevant' we obtained the full‐text articles. Following the <a href="#CD011234-sec-0023">Criteria for considering studies for this review</a> we classified trials into 'to be included' or 'to be excluded'. We documented excluded trials in the category in the <a href="./references#CD011234-sec-0102" title="">Characteristics of excluded studies</a> section. </p> </section> <section id="CD011234-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>Two authors (JE, MM) independently extracted data from trial reports and entered the data into Review Manager (<a href="./references#CD011234-bbs2-0108" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We resolved any differences in opinion through discussion. We used a data collection spreadsheet. We obtained English translations of any trial reported in a language other than English before extracting data. </p> <p>We collected data on trial characteristics as detailed in <a href="./appendices#CD011234-sec-0088">Appendix 7</a>. </p> <p>We obtained the following data on outcomes specified in <a href="#CD011234-sec-0027">Types of outcome measures</a>: for dichotomous outcomes, we collected data on the number of events and total participants followed up in each trial arm; for continuous outcomes, we collected data on the mean and standard deviation in each trial arm. </p> <p>We did not attempt to obtain further information from trialists.</p> </section> <section id="CD011234-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed risk of bias using the Cochrane Collaboration's tool for assessing the risk of bias as described in Chapter 8 of the C<i>ochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011234-bbs2-0102" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD011234-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated the risk ratio (RR) for all dichotomous variables. This was a variation on the protocol ‐ see <a href="#CD011234-sec-0095">Differences between protocol and review</a>. </p> <p>For continuous variables (only data on distance visual acuity were available) we calculated the mean difference. </p> <p>All measures of effect were reported with 95% confidence intervals (CIs).</p> </section> <section id="CD011234-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>Four of the five studies were within‐person studies but were reported as unmatched. We have used these data as reported, which is a conservative analysis. One trial considered one eye per person only, but it was not clear how that eye was selected for inclusion in the trial. </p> </section> <section id="CD011234-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>We documented follow‐up by intervention group. We aimed to collect data on reasons for loss to follow‐up, but this information was not usually available. We documented when loss to follow‐up was high (over 20%), or unbalanced between treatment groups, as a potential source of attrition bias. We planned to conduct an intention‐to‐treat (ITT) analysis if this was reported by the trialists, but we have conducted an available case analysis because the majority of trials did not report an ITT and the one small trial that did only reported one outcome as an ITT analysis (<a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a>). An available case analysis makes the assumption that the treatment effect in people lost to follow‐up was the same as that in people who were observed (assessed). </p> </section> <section id="CD011234-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity by visual inspection of the forest plots and by calculating the I<sup>2</sup> value (<a href="./references#CD011234-bbs2-0101" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. ">Higgins 2002</a>). We also considered the Chi<sup>2</sup> test for heterogeneity, but this may have low power as few trials met the inclusion criteria. </p> </section> <section id="CD011234-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>We were unable to look at small trial effects as we had planned because there were only five included trials. </p> <p>We considered selective outcome reporting bias as part of the assessment of risk of bias in the individual studies (see <a href="#CD011234-sec-0036">Assessment of risk of bias in included studies</a> section). </p> </section> <section id="CD011234-sec-0042"> <h4 class="title">Data synthesis</h4> <p>We pooled data using a random‐effects model, unless there were three or fewer trials, in which case we used a fixed‐effect model. </p> <p>There was considerable heterogeneity, and for many analyses the I<sup>2</sup> statistic was over 50%. In most analyses all effect estimates were in the same direction and we report a pooled value. The exception was <a href="./references#CD011234-fig-0006" title="">Analysis 1.1</a>, but as the effect estimates were relatively close to 1 we have reported a pooled estimate. This is a variation from our protocol ‐ see <a href="#CD011234-sec-0095">Differences between protocol and review</a>. </p> </section> <section id="CD011234-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We did not plan any subgroup analysis at the protocol stage, but there was considerable heterogeneity in terms of baseline risk in participants with non‐proliferative retinopathy and those with proliferative retinopathy. </p> <p>There was not enough evidence to do subgroup analysis based on these groups, and new trials in future are unlikely. </p> </section> <section id="CD011234-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to repeat the analyses excluding studies at high risk of selection, or detection bias, or both. In most analyses trials were similar with respect to these risk of bias domains and so a sensitivity analysis was not possible. We did one sensitivity analysis for the outcome progression of DR. </p> <section id="CD011234-sec-0045"> <h5 class="title">Summary of findings</h5> <p>We report absolute risks and measures of effect in a 'Summary of findings' table, providing an overall assessment of the quality of the evidence for each outcome using the GRADE system (<a href="./references#CD011234-bbs2-0100" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. ">Guyatt 2011</a>). Two review authors (JE, GV) independently performed the GRADE assessment. </p> <p>Our pre‐specified outcome measures were:</p> <p> <ol id="CD011234-list-0003"> <li> <p>proportion of people who lose 15 or more letters (3 lines) of BCVA as measured on a logMAR chart; </p> </li> <li> <p>mean logMAR visual acuity;</p> </li> <li> <p>averse event: loss of driving licence;</p> </li> <li> <p>adverse event: severe visual loss (BCVA &lt; 6/60);</p> </li> <li> <p>adverse event: pain;</p> </li> <li> <p>quality of life measured using a validated questionnaire.</p> </li> </ol> </p> <p>We planned to report outcomes 1, 2 and 6 at one year, outcomes 3 and 4 within three months of treatment and outcome 5 at time of treatment. </p> <p>We modified the protocol to include severe visual loss as an effectiveness outcome measured at one year. See <a href="#CD011234-sec-0095">Differences between protocol and review</a>. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011234-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011234-sec-0046"></div> <section id="CD011234-sec-0047"> <h3 class="title">Description of studies</h3> <section id="CD011234-sec-0048"> <h4 class="title">Results of the search</h4> <p>The electronic searches yielded a total of 3517 references (<a href="#CD011234-fig-0001">Figure 1</a>). The Trials Search Co‐ordinator removed 545 duplicate records, screened the remaining 2972 records and removed 2660 references that were not relevant to the scope of the review. We screened a total of 312 references and discarded 173 reports as these were not relevant to the scope of the review. We reviewed 139 full‐text reports and included 30 reports of five studies that were eligible for inclusion in the review. We were unable to assess 13 reports, either because the full‐text copy was unavailable or because a translation was needed. These reports are listed in the <a href="./references#CD011234-bbs1-0003" title="">Studies awaiting classification</a> section, but are unlikely to be eligible trials. We also excluded 96 reports that referred to 78 trials, see <a href="./references#CD011234-sec-0102" title="">Characteristics of excluded studies</a> for details. </p> <div class="figure" id="CD011234-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Results from searching for studies for inclusion in the review" data-id="CD011234-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Results from searching for studies for inclusion in the review</p> </div> </div> </div> </section> <section id="CD011234-sec-0049"> <h4 class="title">Included studies</h4> <p>We identified five studies that compared laser photocoagulation to a control. Three studies were conducted in the USA (<a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a>; <a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a>; <a href="./references#CD011234-bbs2-0005" title="YassurY , PickleLW , FineSL , SingermanL , OrthDH , PatzA . Optic disc neovascularisation in diabetic retinopathy: II. Natural history and results of photocoagulation treatment. British Journal of Ophthalmology1980;64(2):77‐86. ">Yassur 1980</a>), one study in the UK (<a href="./references#CD011234-bbs2-0003" title="HerculesBL , GayedII , LucasSB , JeacockJ . Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy: a three‐year interim report of a randomised, controlled study using the argon laser. British Journal of Ophthalmology1977;61(9):555‐63. ">Hercules 1977</a>), and one study in Japan (<a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a>). </p> <p>Four studies were within‐person RCTs i.e. one eye was randomly allocated to laser photocoagulation and the other eye to the control (<a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a>; <a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a>; <a href="./references#CD011234-bbs2-0003" title="HerculesBL , GayedII , LucasSB , JeacockJ . Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy: a three‐year interim report of a randomised, controlled study using the argon laser. British Journal of Ophthalmology1977;61(9):555‐63. ">Hercules 1977</a>; <a href="./references#CD011234-bbs2-0005" title="YassurY , PickleLW , FineSL , SingermanL , OrthDH , PatzA . Optic disc neovascularisation in diabetic retinopathy: II. Natural history and results of photocoagulation treatment. British Journal of Ophthalmology1980;64(2):77‐86. ">Yassur 1980</a>). <a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a> randomly allocated people to treatment and only one eye was included in the study; it was unclear how the eye was selected. </p> <p>The number of participants enrolled ranged from 45 in <a href="./references#CD011234-bbs2-0005" title="YassurY , PickleLW , FineSL , SingermanL , OrthDH , PatzA . Optic disc neovascularisation in diabetic retinopathy: II. Natural history and results of photocoagulation treatment. British Journal of Ophthalmology1980;64(2):77‐86. ">Yassur 1980</a> to 3711 in <a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a>. The average age of participants ranged from 41 years in <a href="./references#CD011234-bbs2-0003" title="HerculesBL , GayedII , LucasSB , JeacockJ . Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy: a three‐year interim report of a randomised, controlled study using the argon laser. British Journal of Ophthalmology1977;61(9):555‐63. ">Hercules 1977</a> to 60 years in <a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a>. Most studies recruited participants aged approximately 18 to 70 years with an average age of around 45 years. The percentage of women enrolled ranged from 25% in <a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a> to 48% in <a href="./references#CD011234-bbs2-0005" title="YassurY , PickleLW , FineSL , SingermanL , OrthDH , PatzA . Optic disc neovascularisation in diabetic retinopathy: II. Natural history and results of photocoagulation treatment. British Journal of Ophthalmology1980;64(2):77‐86. ">Yassur 1980</a>, but on average between 40% and 45% of the participants in each trial were women. </p> <p>Two studies enrolled people with PDR only (<a href="./references#CD011234-bbs2-0003" title="HerculesBL , GayedII , LucasSB , JeacockJ . Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy: a three‐year interim report of a randomised, controlled study using the argon laser. British Journal of Ophthalmology1977;61(9):555‐63. ">Hercules 1977</a>; <a href="./references#CD011234-bbs2-0005" title="YassurY , PickleLW , FineSL , SingermanL , OrthDH , PatzA . Optic disc neovascularisation in diabetic retinopathy: II. Natural history and results of photocoagulation treatment. British Journal of Ophthalmology1980;64(2):77‐86. ">Yassur 1980</a>); two studies enrolled people either with moderate or severe non‐proliferative DR or PDR (<a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a>; <a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a>); and one study enrolled participants with pre‐proliferative DR (<a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a>). In the <a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a> study approximately 80% of participants had PDR; in the <a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a> study approximately 20% of participants had PDR. </p> <p>Most studies used PRP with argon laser (<a href="#CD011234-tbl-0002">Table 1</a>). The exception was <a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a>, which evaluated selective photocoagulation of non‐perfusion areas. Three studies compared laser to no treatment (<a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a>; <a href="./references#CD011234-bbs2-0003" title="HerculesBL , GayedII , LucasSB , JeacockJ . Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy: a three‐year interim report of a randomised, controlled study using the argon laser. British Journal of Ophthalmology1977;61(9):555‐63. ">Hercules 1977</a>; <a href="./references#CD011234-bbs2-0005" title="YassurY , PickleLW , FineSL , SingermanL , OrthDH , PatzA . Optic disc neovascularisation in diabetic retinopathy: II. Natural history and results of photocoagulation treatment. British Journal of Ophthalmology1980;64(2):77‐86. ">Yassur 1980</a>); two studies compared laser to deferred laser treatment (<a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a>; <a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a>; i.e. control participants received laser when severe non‐proliferative (<a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a>) or PDR (<a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a>; <a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a>) developed). </p> <div class="table" id="CD011234-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of laser photocoagulation</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of photocoagulation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number (size) of burns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intensity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Exposure time (seconds)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of sessions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Argon</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Panretinal</p> <p>Focal treatment of new vessels</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>800‐1600 (500 µm) or</p> <p>500‐1000 (1000 µm)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (usually)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Argon</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Panretinal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full: 1200‐1600 (500 µm)</p> <p>Mild: 400‐650 (500 µm)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full: 2 or more</p> <p>Mild: 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011234-bbs2-0003" title="HerculesBL , GayedII , LucasSB , JeacockJ . Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy: a three‐year interim report of a randomised, controlled study using the argon laser. British Journal of Ophthalmology1977;61(9):555‐63. ">Hercules 1977</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Argon</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Panretinal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>800 to 3000 (200 µm and 500 µm)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minimal retinal blanching</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Up to 6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Selective photocoagulation of non‐perfusion areas</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(400 µm‐500 µm)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011234-bbs2-0005" title="YassurY , PickleLW , FineSL , SingermanL , OrthDH , PatzA . Optic disc neovascularisation in diabetic retinopathy: II. Natural history and results of photocoagulation treatment. British Journal of Ophthalmology1980;64(2):77‐86. ">Yassur 1980</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Argon</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Panretinal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As for <a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As for <a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As for <a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As for <a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a> </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD011234-sec-0050"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD011234-sec-0102" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD011234-sec-0051"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD011234-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD011234-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011234-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011234-sec-0052"> <h4 class="title">Allocation</h4> <p>Generation of the allocation sequence was considered adequate in two trials (<a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a>; <a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a>) and was not clearly described in the rest. As most of the studies were within‐person studies, allocation concealment was not judged to be a problem (as all participants received both intervention and control). In the one parallel group study the allocation was clearly described and judged to be at low risk of bias (<a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a>). </p> </section> <section id="CD011234-sec-0053"> <h4 class="title">Blinding</h4> <p>We judged the studies that measured and reported visual acuity to be at a high risk of bias because the treatment and control groups were obviously different and patient knowledge of intervention could affect the measurement of visual acuity. However, the extent of the bias is difficult to judge, and some studies had specific protocols to improve the accuracy of the measurement of vision, such as encouraging patients to read as far down the chart as possible (<a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a>). In general, we judged that patient and carer knowledge of assignment would not affect the progression of DR. </p> </section> <section id="CD011234-sec-0054"> <h4 class="title">Incomplete outcome data</h4> <p>We judged within‐person studies to be at low risk of attrition bias by definition because, although there may be attrition in patient follow‐up, the follow‐up between intervention and control groups, i.e. between eyes, will always be equal. However, two studies selectively removed participants who received treatment in the control eye (<a href="./references#CD011234-bbs2-0003" title="HerculesBL , GayedII , LucasSB , JeacockJ . Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy: a three‐year interim report of a randomised, controlled study using the argon laser. British Journal of Ophthalmology1977;61(9):555‐63. ">Hercules 1977</a>; <a href="./references#CD011234-bbs2-0005" title="YassurY , PickleLW , FineSL , SingermanL , OrthDH , PatzA . Optic disc neovascularisation in diabetic retinopathy: II. Natural history and results of photocoagulation treatment. British Journal of Ophthalmology1980;64(2):77‐86. ">Yassur 1980</a>), which we considered to be a potential source of bias for the effect estimate. The one parallel group study had considerable loss to follow‐up (<a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a>). </p> </section> <section id="CD011234-sec-0055"> <h4 class="title">Selective reporting</h4> <p>In general reporting bias was difficult to judge with the information available. None of the studies reported all our review outcomes. </p> </section> <section id="CD011234-sec-0056"> <h4 class="title">Other potential sources of bias</h4> <p>The <a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a> study was stopped early. </p> </section> </section> <section id="CD011234-sec-0057"> <h3 class="title" id="CD011234-sec-0057">Effects of interventions</h3> <p>See: <a href="./full#CD011234-tbl-0001"><b>Summary of findings for the main comparison</b> Laser photocoagulation compared to control for diabetic retinopathy</a> </p> <section id="CD011234-sec-0058"> <h4 class="title">1.1 Loss of 15 or more letters BCVA at 12 months</h4> <p>For this outcome we found two relevant trials (<a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a>; <a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a>: n = 8926; <a href="#CD011234-fig-0003">Figure 3</a>; <a href="./references#CD011234-fig-0006" title="">Analysis 1.1</a>). One of these studies reported loss of 10 or more letters rather than loss of 15 or more letters (<a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a>). There was considerable heterogeneity of effect (I<sup>2</sup> = 69%; P value = 0.07). In the <a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a> study fewer eyes given laser photocoagulation lost 10 or more letters compared to untreated eyes, but there was uncertainty and the confidence intervals included 1 (RR 0.86, 95% CI 0.71 to 1.04). In the <a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a> study more eyes treated with laser photocoagulation lost 15 or more letters over 12 months compared to eyes given deferred treatment, but again there was uncertainty and the confidence intervals included 1 (RR 1.07, 95% CI 0.92 to 1.23). </p> <div class="figure" id="CD011234-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Laser photocoagulation versus control, outcome: 1.1 Loss of 15 or more letters BCVA at 12 months" data-id="CD011234-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Laser photocoagulation versus control, outcome: 1.1 Loss of 15 or more letters BCVA at 12 months </p> </div> </div> </div> </section> <section id="CD011234-sec-0059"> <h4 class="title">1.2 Loss of 15 or more letters BCVA at longer follow‐up times</h4> <p>Two trials reported this outcome at two years (<a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a>; <a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a>: n = 8306; <a href="./references#CD011234-fig-0007" title="">Analysis 1.2</a>). Fewer eyes given laser photocoagulation lost 15 (or 10) or more lines of visual acuity at two years compared to untreated (<a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a>), or deferred treatment eyes (<a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a>; RR 0.88, 95% CI 0.80 to 0.97). There was considerable heterogeneity I<sup>2</sup> = 73%, P value = 0.06). However, as both effect estimates were in the same direction (0.74 and 0.92) we have reported a pooled estimate. </p> <p>Two trials reported this outcome at three years (<a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a>; <a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a>: n = 7458; <a href="./references#CD011234-fig-0008" title="">Analysis 1.3</a>). More eyes receiving laser photocoagulation lost 15 or more letters BCVA at three years compared to eyes with deferred treatment, but there was uncertainty in the result and the confidence intervals included 1 (RR 1.07, 95% CI 0.93 to 1.23). The results of the two trials were reasonably consistent I<sup>2</sup> = 14%. </p> <p>No trials reported this outcome at four years.</p> <p>One study reported this outcome at five years (<a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a>; n = 7422). Eyes receiving laser photocoagulation were less likely to lose 15 or more letters compared to eyes receiving deferred treatment (RR 0.79, 95% CI 0.72 to 0.85). </p> </section> <section id="CD011234-sec-0060"> <h4 class="title">1.3 Mean BCVA at 12 months</h4> <p>One study reported mean logMAR BCVA at three years (<a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a>). The difference between the groups was small and uncertain (MD 0.02, 95% CI ‐0.23 to 0.27; n = 36). </p> </section> <section id="CD011234-sec-0061"> <h4 class="title">2 Mean NVA at 12 months</h4> <p>None of the studies reported near visual acuity.</p> </section> <section id="CD011234-sec-0062"> <h4 class="title">3 Severe visual loss (BCVA &lt; 6/60)</h4> <p>For the outcome of severe visual loss (BCVA &lt; 6/60) we found four relevant trials (<a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a>; <a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a>; <a href="./references#CD011234-bbs2-0003" title="HerculesBL , GayedII , LucasSB , JeacockJ . Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy: a three‐year interim report of a randomised, controlled study using the argon laser. British Journal of Ophthalmology1977;61(9):555‐63. ">Hercules 1977</a>; <a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a>: n = 9276; <a href="#CD011234-fig-0004">Figure 4</a>; <a href="./references#CD011234-fig-0009" title="">Analysis 1.4</a>). Eyes receiving laser photocoagulation were less likely to experience severe visual loss compared to untreated eyes or eyes that received deferred treatment (RR 0.46, 95% CI 0.24 to 0.86). This outcome had high levels of heterogeneity (I<sup>2</sup> = 70%, P value = 0.02), but as all the effect estimates were in the same direction we report a pooled estimate. Such heterogeneity seemed due to <a href="./references#CD011234-bbs2-0003" title="HerculesBL , GayedII , LucasSB , JeacockJ . Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy: a three‐year interim report of a randomised, controlled study using the argon laser. British Journal of Ophthalmology1977;61(9):555‐63. ">Hercules 1977</a>, a small study including only patients with proliferative retinopathy, which recorded the largest benefit with laser. </p> <div class="figure" id="CD011234-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Laser photocoagulation versus control, outcome: 1.4 Severe visual loss (BCVA &lt; 6/60)" data-id="CD011234-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Laser photocoagulation versus control, outcome: 1.4 Severe visual loss (BCVA &lt; 6/60) </p> </div> </div> </div> </section> <section id="CD011234-sec-0063"> <h4 class="title">4 Progression of diabetic retinopathy</h4> <p>For the outcome of progression of DR we found four relevant trials (<a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a>; <a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a>; <a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a>; <a href="./references#CD011234-bbs2-0005" title="YassurY , PickleLW , FineSL , SingermanL , OrthDH , PatzA . Optic disc neovascularisation in diabetic retinopathy: II. Natural history and results of photocoagulation treatment. British Journal of Ophthalmology1980;64(2):77‐86. ">Yassur 1980</a>: n = 8331; <a href="#CD011234-fig-0005">Figure 5</a>; <a href="./references#CD011234-fig-0010" title="">Analysis 1.5</a>). </p> <div class="figure" id="CD011234-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Laser photocoagulation versus control, outcome: 1.5 Progression of diabetic retinopathy" data-id="CD011234-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Laser photocoagulation versus control, outcome: 1.5 Progression of diabetic retinopathy </p> </div> </div> </div> <p>In the <a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a> study progression was based on grading of fundus photographs. Eyes were graded for new vessels and severity was graded by comparison with standard images. The following categories were used and progression was defined as change of one or more grades from no new vessels to moderate or severe NVD (NVD means new vessels on or within 1 disc diameter of the optic disc; NVE means new vessels elsewhere): </p> <p> <ol id="CD011234-list-0004"> <li> <p>no new vessels;</p> </li> <li> <p>mild NVE, no NVD;</p> </li> <li> <p>moderate or severe NVE, no NVD;</p> </li> <li> <p>mild NVD;</p> </li> <li> <p>moderate or severe NVD.</p> </li> </ol> </p> <p>In the <a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a> study progression was defined as the development of 'high risk proliferative diabetic retinopathy'. This was defined as PDR with high risk characteristics as defined by <a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a>. These were new vessels on or within 1 disc diameter of the optic disc worse than a standard photograph, with or without vitreous or preretinal haemorrhage; or vitreous or preretinal haemorrhage accompanied by new vessels, either NVD (less than standard photograph) or NVE greater than or equal to a quarter of the disc area. </p> <p>In <a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a> progression was defined as the development of PDR, i.e. the growth of new vessels (detected by ophthalmoscopy or fluorescein angiography), or preretinal/vitreous haemorrhage. </p> <p><a href="./references#CD011234-bbs2-0005" title="YassurY , PickleLW , FineSL , SingermanL , OrthDH , PatzA . Optic disc neovascularisation in diabetic retinopathy: II. Natural history and results of photocoagulation treatment. British Journal of Ophthalmology1980;64(2):77‐86. ">Yassur 1980</a> considered only new vessels on or near the optic disc. These were graded into five grades of severity based on the number of involved disc quadrants, calibre of the new vessels, density of neovascularisation (NVD) or fibrous proliferation at the disc (FPD), total area of NVD or FPD proliferation, plane of NVD or FPD proliferation, and fluorescein leakage from NVD. Progression was defined as increase in severity of one or more grades. </p> <p>The time frames at which these outcomes were reported were different ‐ ranging from 12 months to five years, and these are indicated on the figure. </p> <p>DR was less likely to progress in eyes that received laser photocoagulation (RR 0.49, 95% CI 0.37 to 0.64). There was considerable heterogeneity I<sup>2</sup> = 63%, P value = 0.05) but all effect estimates were in the same direction, so we report a pooled estimate. </p> </section> <section id="CD011234-sec-0064"> <h4 class="title">5 Quality of life</h4> <p>None of the included studies reported quality of life.</p> </section> <section id="CD011234-sec-0065"> <h4 class="title">6.1 Adverse events: pain</h4> <p>None of the included studies reported pain.</p> </section> <section id="CD011234-sec-0066"> <h4 class="title">6.2 Adverse events: loss of driving licence</h4> <p>None of the included studies reported patient outcomes such as loss of driving licence.</p> </section> <section id="CD011234-sec-0067"> <h4 class="title">6.3 Adverse events: vitreous haemorrhage</h4> <p>For this outcome of vitreous haemorrhage we found two relevant trials (<a href="./references#CD011234-bbs2-0003" title="HerculesBL , GayedII , LucasSB , JeacockJ . Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy: a three‐year interim report of a randomised, controlled study using the argon laser. British Journal of Ophthalmology1977;61(9):555‐63. ">Hercules 1977</a>; <a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a>: n = 224; <a href="./references#CD011234-fig-0011" title="">Analysis 1.6</a>). People receiving laser photocoagulation were less likely to develop vitreous haemorrhage (RR 0.56, 95% CI 0.37 to 0.85; I<sup>2</sup> = 0%). </p> </section> <section id="CD011234-sec-0068"> <h4 class="title">6.4 Adverse events: retinal detachment</h4> <p>None of the studies reported retinal detachment by intervention group.</p> </section> <section id="CD011234-sec-0069"> <h4 class="title">Sensitivity analysis</h4> <p>For <a href="./references#CD011234-fig-0010" title="">Analysis 1.5</a> progression of diabetic retinopathy, exclusion of two trials at high risk of selection or detection bias resulted in a RR of 0.55 (95% CI 0.48 to 0.64; participants = 8183; studies = 2; I<sup>2</sup> = 41%; <a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a>; <a href="./references#CD011234-bbs2-0005" title="YassurY , PickleLW , FineSL , SingermanL , OrthDH , PatzA . Optic disc neovascularisation in diabetic retinopathy: II. Natural history and results of photocoagulation treatment. British Journal of Ophthalmology1980;64(2):77‐86. ">Yassur 1980</a>). This is not dissimilar to the analysis of all four trials (RR 0.49, 95% CI 0.37 to 0.64; participants = 8331; studies = 4; I<sup>2</sup> = 63%). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011234-sec-0070" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011234-sec-0070"></div> <section id="CD011234-sec-0071"> <h3 class="title" id="CD011234-sec-0071">Summary of main results</h3> <p>See <a href="./full#CD011234-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>We identified five trials. In the majority of these studies (4 trials, 99% of all participants) the intervention was panretinal photocoagulation (PRP) using an argon laser. There were differences in the patient population included in these studies. Two trials included 94% of the participants in this review (<a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a>; <a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a>). These two studies were conducted in the US population and were complementary: <a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a> assessed whether PRP is effective compared to no treatment in people mostly affected by proliferative diabetic retinopathy (PDR); <a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a> assessed whether earlier peripheral laser treatment of diabetic retinopathy (DR) in its non‐proliferative or early proliferative stage is beneficial, compared to a strategy in which laser is used at a later stage, in high‐risk PDR. Thus, any benefit in <a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a> should have been less than that seen in <a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a> as laser is also part of the control strategy in the former. In most of the analyses the effects observed in <a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a> were indeed lower than <a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a> but not significantly so. Even though there was evidence for statistical heterogeneity, effects were generally in the same direction, so we pooled the results to obtain (approximate) overall estimates of effect. </p> <p>At 12 months there was little difference between eyes receiving laser photocoagulation and those allocated to no treatment (or deferred treatment), in terms of loss of 15 or more letters of visual acuity. Longer term follow‐up did not show a consistent pattern, but <a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a> reported a 20% reduction in risk of loss of 15 or more letters of visual acuity at five years. </p> <p>Treatment with laser reduced the risk of severe visual loss by over 50% at 12 months.</p> <p>There was a beneficial effect on progression of DR with treated eyes experiencing a 50% reduction in risk of progression and a similar reduction in risk of vitreous haemorrhage. </p> <p>None of the studies reported near visual acuity, quality of life, pain, or patient relevant outcomes such as loss of driving licence or adverse effects such as retinal detachment. </p> </section> <section id="CD011234-sec-0072"> <h3 class="title" id="CD011234-sec-0072">Overall completeness and applicability of evidence</h3> <p>Overall there is not a large amount of evidence from randomised controlled trials (RCTs) on laser photocoagulation compared to no treatment or deferred treatment. The evidence is dominated by two large studies conducted in the US population (<a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a>; <a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a>). </p> <p>Reflecting the fact that the studies were conducted some time ago, there was a lack of data reported for many of our current pre‐specified review outcomes, in particular patient‐relevant outcomes such as quality of life. </p> <p>We did not consider lasers that are not commonly used today but the treatment parameters used in the included trials were different to those in current use, in particular, smaller size and shorter duration burns are now used (<a href="./references#CD011234-bbs2-0107" title="Royal College of Ophthalmologists. Diabetic Retinopathy Guidelines 2012. www.rcophth.ac.uk/page.asp?section=451 (accessed 14 March 2014). ">RCOphth 2012</a>). </p> <p>Overall the evidence is applicable to people presenting with moderate to severe pre‐proliferative and PDR, however, the fact that relatively few trials were identified, and that these were all conducted some time ago in high‐income countries leaves a lack of evidence for lower‐ and middle‐income countries and different parts of the world. However, we have no reason to suppose that the effectiveness of these treatments would be different in lower‐income countries. </p> <p>The introduction of anti‐vascular endothelial growth factor (anti‐VEGF) therapy for treating several chorioretinal vascular diseases has made it possible to achieve a rapid, but transient, regression of new vessels in PDR, especially to try to clear vitreous haemorrhage, but also to limit side effects of PRP regarding the occurrence of diabetic macular oedema in patients at risk. Moreover, anti‐VEGF therapy is sometimes used in preparation of vitrectomy ‐ which includes use of an endolaser ‐ in advanced PDR. However, use of anti‐VEGF in PDR may have adverse effects and requires multiple treatments. Other Cochrane Reviews compare the effectiveness of anti‐VEGF and laser treatment for PDR (<a href="./references#CD011234-bbs2-0104" title="Martinez‐ZapataMJ , Martí‐CarvajalAJ , SolàI , PijoánJI , Buil‐CalvoJA , CorderoJA , EvansJR . Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD008721.pub2] ">Martinez‐Zapata 2014</a>), and diabetic macular oedema (<a href="./references#CD011234-bbs2-0110" title="VirgiliG , ParravanoM , MenchiniF , BrunettiM . Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD007419.pub3] ">Virgili 2012</a>). </p> </section> <section id="CD011234-sec-0073"> <h3 class="title" id="CD011234-sec-0073">Quality of the evidence</h3> <p>Overall there is not a large amount of evidence from RCTs on the effects of laser photocoagulation compared to no treatment or deferred treatment. The evidence is dominated by two large studies conducted in the US population (<a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a>; <a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a>). These two studies were generally judged to be at low or unclear risk of bias, with the exception of inevitable unmasking of patients due to differences between intervention and control. </p> <p>Four of the studies were within‐person (i.e. pair‐matched), but none of the studies reported the results taking into account the matching. This means that the results will be conservative (confidence intervals wider than if matching had been taken into account). One study reported that they had repeated the analyses taking into account the pair‐matching and that ignoring the pair‐matching was indeed a conservative approach (<a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a>). </p> <p>Overall we judged the quality of the evidence to be moderate or low (<a href="./full#CD011234-tbl-0001">summary of findings Table for the main comparison</a>), reflecting the fact that the studies contributing to the review were conducted some time ago, when standards of trial conduct and reporting were lower; heterogeneity was also present. </p> </section> <section id="CD011234-sec-0074"> <h3 class="title" id="CD011234-sec-0074">Potential biases in the review process</h3> <p>We followed standard methods expected by the Cochrane Collaboration. All changes from protocol are documented in <a href="#CD011234-sec-0095">Differences between protocol and review</a>. </p> </section> <section id="CD011234-sec-0075"> <h3 class="title" id="CD011234-sec-0075">Agreements and disagreements with other studies or reviews</h3> <p>In current clinical guidelines, e.g. <a href="./references#CD011234-bbs2-0107" title="Royal College of Ophthalmologists. Diabetic Retinopathy Guidelines 2012. www.rcophth.ac.uk/page.asp?section=451 (accessed 14 March 2014). ">RCOphth 2012</a>, PRP is recommended in high‐risk PDR. The recommendation is that <i>"as retinopathy approaches the proliferative stage, laser scatter treatment (PRP) should be increasingly considered to prevent progression to high risk PDR"</i> based on other factors such as patients' compliance or planned cataract surgery. </p> <p>These recommendations need to be interpreted while considering the risk of visual loss associated with different levels of severity of DR, as well as the risk of progression. Since PRP reduces the risk of severe visual loss, but not moderate visual loss that is more related to diabetic maculopathy, most ophthalmologists judge that there is little benefit in treating non‐proliferative DR at low risk of severe visual damage, as patients would incur the known adverse effects of PRP, which, although mild, include pain and peripheral visual field loss and transient DMO. The results of this review would confirm this approach. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011234-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/urn:x-wiley:14651858:media:CD011234:CD011234-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_t/tCD011234-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Results from searching for studies for inclusion in the review" data-id="CD011234-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Results from searching for studies for inclusion in the review</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/full#CD011234-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011234-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/urn:x-wiley:14651858:media:CD011234:CD011234-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_t/tCD011234-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011234-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/full#CD011234-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011234-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/urn:x-wiley:14651858:media:CD011234:CD011234-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_t/tCD011234-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Laser photocoagulation versus control, outcome: 1.1 Loss of 15 or more letters BCVA at 12 months" data-id="CD011234-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Laser photocoagulation versus control, outcome: 1.1 Loss of 15 or more letters BCVA at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/full#CD011234-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011234-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/urn:x-wiley:14651858:media:CD011234:CD011234-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_t/tCD011234-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Laser photocoagulation versus control, outcome: 1.4 Severe visual loss (BCVA &lt; 6/60)" data-id="CD011234-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Laser photocoagulation versus control, outcome: 1.4 Severe visual loss (BCVA &lt; 6/60) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/full#CD011234-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011234-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/urn:x-wiley:14651858:media:CD011234:CD011234-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_t/tCD011234-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Laser photocoagulation versus control, outcome: 1.5 Progression of diabetic retinopathy" data-id="CD011234-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Laser photocoagulation versus control, outcome: 1.5 Progression of diabetic retinopathy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/full#CD011234-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011234-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/urn:x-wiley:14651858:media:CD011234:CD011234-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_t/tCD011234-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Laser photocoagulation versus control, Outcome 1 Loss of 15 or more letters BCVA at 12 months." data-id="CD011234-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Laser photocoagulation versus control, Outcome 1 Loss of 15 or more letters BCVA at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/references#CD011234-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011234-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/urn:x-wiley:14651858:media:CD011234:CD011234-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_t/tCD011234-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Laser photocoagulation versus control, Outcome 2 Loss of 15 or more letters BCVA at 2 years." data-id="CD011234-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Laser photocoagulation versus control, Outcome 2 Loss of 15 or more letters BCVA at 2 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/references#CD011234-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011234-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/urn:x-wiley:14651858:media:CD011234:CD011234-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_t/tCD011234-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Laser photocoagulation versus control, Outcome 3 Loss of 15 or more letters BCVA at 3 years." data-id="CD011234-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Laser photocoagulation versus control, Outcome 3 Loss of 15 or more letters BCVA at 3 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/references#CD011234-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011234-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/urn:x-wiley:14651858:media:CD011234:CD011234-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_t/tCD011234-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Laser photocoagulation versus control, Outcome 4 Severe visual loss (BCVA &lt; 6/60)." data-id="CD011234-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Laser photocoagulation versus control, Outcome 4 Severe visual loss (BCVA &lt; 6/60). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/references#CD011234-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011234-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/urn:x-wiley:14651858:media:CD011234:CD011234-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_t/tCD011234-CMP-001-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Laser photocoagulation versus control, Outcome 5 Progression of diabetic retinopathy." data-id="CD011234-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Laser photocoagulation versus control, Outcome 5 Progression of diabetic retinopathy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/references#CD011234-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011234-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/urn:x-wiley:14651858:media:CD011234:CD011234-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_t/tCD011234-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Laser photocoagulation versus control, Outcome 6 Vitreous haemorrhage." data-id="CD011234-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Laser photocoagulation versus control, Outcome 6 Vitreous haemorrhage.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/references#CD011234-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/media/CDSR/CD011234/image_n/nCD011234-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011234-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Laser photocoagulation compared to control for diabetic retinopathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Laser photocoagulation compared to no treatment (or deferred treatment) for diabetic retinopathy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with diabetic retinopathy<br/> <b>Settings:</b> Ophthalmology clinics<br/> <b>Intervention:</b> laser photocoagulation<br/> <b>Comparison:</b> no treatment or deferred treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk*</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No treatment or deferred treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Laser photocoagulation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Loss of 15 or more letters BCVA</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low risk (non‐proliferative DR)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.99<br/> (0.89 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>8926<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The pooled RR 0.99 (0.89 to 1.11) is derived from one study with mainly low risk population RR 1.07 (0.92 to 1.23) and one study with mainly high risk population 0.86 (0.71 to 1.04) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>99 per 1000<br/> (89 to 111) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk (proliferative DR)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>248 per 1000<br/> (223 to 278) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BCVA measured using logMAR acuity (0 = 6/6 visual acuity, higher score is worse visual acuity) </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BCVA at 12 months in the control group was 0.12 logMAR</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BCVA at 12 months in the intervention group was 0.02 logMAR units higher (worse; 0.23 lower to 0.27 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Severe visual loss (BCVA &lt; 6/60)</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low risk (non‐proliferative DR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>RR 0.46<br/> (0.24 to 0.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>9276<br/> (4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 per 1000<br/> (2 to 9) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High risk (proliferative DR)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>23 per 1000<br/> (12 to 43) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Progression of diabetic retinopathy</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low risk (non‐proliferative DR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>RR 0.49<br/> (0.37 to 0.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>8331<br/> (4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>⊕⊕⊝⊝<br/> LOW <sup>1,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>100 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>49 per 1000<br/> (37 to 64) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk (proliferative DR)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>400 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>196 per 1000</p> <p>(148 to 256)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> <p>Follow‐up: at time of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loss of driving licence</p> <p>Follow‐up: within three months of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>DR</b> : diabetic retinopathy; <b>BCVA</b>: Best corrected visual acuity </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Estimates of assumed risk are indicative only, as estimates at 12 months were not available in all studies. For the low risk populations they were estimated from ETDRS (but acknowledging that the control group received deferred laser) and for the high risk populations they were estimated from DRS and Hercules 1977. </p> <p><sup>1</sup>Downgraded for risk of bias (‐1): studies were not masked and treatment groups different </p> <p><sup>2</sup>Downgraded for inconsistency (‐1): I<sup>2</sup> = 69% and effect estimates were in different directions. See comments for details </p> <p><sup>3</sup>Downgraded for imprecision (‐1): wide confidence intervals </p> <p><sup>4</sup> There was heterogeneity (I<sup>2</sup> = 70%) but all effect estimates favoured laser photocoagulation so we did not downgrade for inconsistency </p> <p><sup>5</sup>Downgraded for indirectness (‐1): study results were reported at 1, 3, 4 and 5 years </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Laser photocoagulation compared to control for diabetic retinopathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/full#CD011234-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011234-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of laser photocoagulation</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of photocoagulation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number (size) of burns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intensity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Exposure time (seconds)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of sessions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Argon</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Panretinal</p> <p>Focal treatment of new vessels</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>800‐1600 (500 µm) or</p> <p>500‐1000 (1000 µm)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (usually)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011234-bbs2-0002" title="Anonymous . Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology1991;98(5 Suppl):741‐56. Anonymous . Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):766‐85. Anonymous . Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):757‐65. Anonymous . Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Archives of Ophthalmology1995;113(9):1144‐55. Anonymous . Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991;98(5 Suppl):823‐33. ChewEY , FerrisFL , CsakyKG , MurphyRP , AgrónE , ThompsonDJ , et al. The long‐term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow‐up study. Ophthalmology2003;110(9):1683‐9. ChewEY , KleinML , FerrisFL , RemaleyNA , MurphyRP , ChantryK , et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology1996;114(9):1079‐84. ChewEY , KleinML , MurphyRP , RemaleyNA , FerrisFL . Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Archives of Ophthalmology1995;113(1):52‐5. ChuiL , SaltiHI , CavalleranoJD , StockmanME , ArriggPG , ShahST , et al. Fifteen year followup of the ocular and medical status of Early Treatment Diabetic Retinopathy Study (ETDRS) patients enrolled at the Joslin Diabetes Center. Investigative Ophthalmology and Visual Science2005:ARVO E‐abstract 4671. DavisMD , FisherMR , GangnonRE , BartonF , AielloLM , ChewEY , et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Investigative Ophthalmology and Visual Science1998;39(2):233‐52. FerrisF . Early photocoagulation in patients with either type I or type II diabetes. Transactions of the American Ophthalmological Society1996;94:505‐37. FongDS , BartonFB , BresnickGH . Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15. American Journal of Ophthalmology1999;128(5):612‐7. FongDS , FerrisFL , DavisMD , ChewEY . Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. American Journal of Ophthalmology1999;127(2):137‐41. FongDS , MyersFL , SegasPP , HubbardLM , DavisMD , FerrisFL . Subretinal fibrosis in patients with diabetic retinopathy. Investigative Ophthalmology and Visual Science1995;36:ARVO E‐abstract 3796. ">ETDRS 1991</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Argon</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Panretinal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full: 1200‐1600 (500 µm)</p> <p>Mild: 400‐650 (500 µm)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Full: 2 or more</p> <p>Mild: 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011234-bbs2-0003" title="HerculesBL , GayedII , LucasSB , JeacockJ . Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy: a three‐year interim report of a randomised, controlled study using the argon laser. British Journal of Ophthalmology1977;61(9):555‐63. ">Hercules 1977</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Argon</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Panretinal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>800 to 3000 (200 µm and 500 µm)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minimal retinal blanching</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Up to 6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011234-bbs2-0004" title="SatoY . Retinal photocoagulation for diabetic retinopathies. Japanese Journal of Clinical Medicine2005;63(Suppl 6):256‐62. SatoY , KojimaharaN , KitanoS , KatoS , AndoN , YamaguchiN , et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Japanese Journal of Ophthalmology2012;56(1):52‐9. ">Sato 2012</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Selective photocoagulation of non‐perfusion areas</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(400 µm‐500 µm)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011234-bbs2-0005" title="YassurY , PickleLW , FineSL , SingermanL , OrthDH , PatzA . Optic disc neovascularisation in diabetic retinopathy: II. Natural history and results of photocoagulation treatment. British Journal of Ophthalmology1980;64(2):77‐86. ">Yassur 1980</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Argon</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Panretinal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As for <a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As for <a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As for <a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As for <a href="./references#CD011234-bbs2-0001" title="Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):1‐226. Anonymous . Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. International Ophthalmology Clinics1987;27(4):239‐53. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology1981;88(7):583‐600. Anonymous . Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology1978;85(1):82‐106. Anonymous . Report Number 6. Design, methods, and baseline results. Investigative Ophthalmology and Visual Science1981;21(1 Pt 2):149‐226. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology1991;98(2):125‐8. BlankenshipGW . Fifteen‐year argon laser and xenon photocoagulation visual results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Transactions of the American Ophthalmological Society1990;88:179‐85. DrummondMF , DaviesLM , FerrisFL . Assessing the costs and benefits of medical research: the diabetic retinopathy study. Social Science and Medicine1992;34(9):973‐81. EdererF , PodgorMJ . Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9. Controlled Clinical Trials1984;5(4):373‐81. KaufmanSC , FerrisFL3rd , SeigelDG , DavisMD , DeMetsDL . Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Investigative Ophthalmology and Visual Science1989;30(1):23‐8. KaufmanSC , FerrisFL , SwartzM . Intraocular pressure following panretinal photocoagulation for diabetic retinopathy. Diabetic Retinopathy Report No. 11. Archives of Ophthalmology1987;105(6):807‐9. KnatterudGL . Mortality experience in the diabetic retinopathy study. Israel Journal of Medical Sciences1983;19(4):424‐8. ">DRS 1978</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of laser photocoagulation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/full#CD011234-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011234-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Laser photocoagulation versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Loss of 15 or more letters BCVA at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8926</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.89, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Loss of 15 or more letters BCVA at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.80, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Loss of 15 or more letters BCVA at 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.93, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Severe visual loss (BCVA &lt; 6/60) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.24, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Progression of diabetic retinopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.37, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Vitreous haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.37, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Laser photocoagulation versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011234.pub2/references#CD011234-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011234.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011234-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011234-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD011234-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD011234-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD011234-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011234\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011234\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011234\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011234\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011234\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011234\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011234\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011234\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011234\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011234\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011234\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011234\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011234\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011234\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011234\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011234\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011234\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011234\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XHP2gG4h&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011234.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011234.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011234.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011234.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011234.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719080622"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011234.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719080625"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011234.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de00659111be4',t:'MTc0MDcxOTA4MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 